Resultados da pesquisa - Semiond, Dorothée

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors Por Ferron, Géraldine M., Dai, Yang, Semiond, Dorothée

Obter o texto integral Obter o texto integral Obter o texto integral

Preclinical profile of cabazitaxel Por Vrignaud, Patricia, Semiond, Dorothée, Benning, Veronique, Beys, Eric, Bouchard, Hervé, Gupta, Sunil

Obter o texto integral Obter o texto integral Obter o texto integral

Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood–brain barrier in mice and rats Por Cisternino, Salvatore, Bourasset, Fanchon, Archimbaud, Yves, Sémiond, Dorothée, Sanderink, Gérard, Scherrmann, Jean-Michel

Obter o texto integral Obter o texto integral Obter o texto integral

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours Por Fumoleau, Pierre, Trigo, Jose Manuel, Isambert, Nicolas, Sémiond, Dorothée, Gupta, Sunil, Campone, Mario

Obter o texto integral Obter o texto integral Obter o texto integral

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients Por Fau, Jean‐Baptiste, El‐Cheikh, Raouf, Brillac, Claire, Koiwai, Kimiko, Mace, Nathalie, Campana, Frank, Semiond, Dorothee, Nguyen, Laurent

Obter o texto integral Obter o texto integral Obter o texto integral

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone Por Thai, Hoai‐Thu, Gaudel, Nadia, Cerou, Marc, Ayral, Geraldine, Fau, Jean‐Baptiste, Sebastien, Bernard, van de Velde, Helgi, Semiond, Dorothée, Veyrat‐Follet, Christine

Obter o texto integral Obter o texto integral Obter o texto integral

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma Por Mikhael, Joseph, Richardson, Paul, Usmani, Saad Z., Raje, Noopur, Bensinger, William, Karanes, Chatchada, Campana, Frank, Kanagavel, Dheepak, Dubin, Franck, Liu, Qianying, Semiond, Dorothée, Anderson, Kenneth

Obter o texto integral Obter o texto integral Obter o texto integral

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma Por Koiwai, Kimiko, El‐Cheikh, Raouf, Thai, Hoai‐Thu, Brillac, Claire, Fau, Jean‐Baptiste, Veyrat‐Follet, Christine, Risse, Marie‐Laure, van de Velde, Helgi, Semiond, Dorothée, Nguyen, Laurent

Obter o texto integral Obter o texto integral Obter o texto integral

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myelom... Por Rachedi, Fatiha, Koiwai, Kimiko, Gaudel‐Dedieu, Nadia, Sebastien, Bernard, Thai, Hoai‐Thu, Brillac, Claire, Fau, Jean Baptiste, Nguyen, Laurent, van de Velde, Helgi, Veyrat‐Follet, Christine, Semiond, Dorothée

Obter o texto integral Obter o texto integral Obter o texto integral

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis Por Dimopoulos, Meletios A., Leleu, Xavier, Moreau, Philippe, Richardson, Paul G., Liberati, Anna Marina, Harrison, Simon J., Miles Prince, H., Ocio, Enrique M., Assadourian, Sylvie, Campana, Frank, Malinge, Laure, Sémiond, Dorothée, van de Velde, Helgi, Yong, Kwee

Obter o texto integral Obter o texto integral Obter o texto integral

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab Por Mikhael, Joseph, Belhadj-Merzoug, Karim, Hulin, Cyrille, Vincent, Laure, Moreau, Philippe, Gasparetto, Cristina, Pour, Ludek, Spicka, Ivan, Vij, Ravi, Zonder, Jeffrey, Atanackovic, Djordje, Gabrail, Nashat, Martin, Thomas G., Perrot, Aurore, Bensfia, Samira, Weng, Qilong, Brillac, Claire, Semiond, Dorothée, Macé, Sandrine, Corzo, Kathryn P., Leleu, Xavier

Obter o texto integral Obter o texto integral Obter o texto integral